Hyper II DHA/EPA, 100 Count Softgels. Product labeling reads in part:"Hyper II DHA/EPA Refined Deep Sea Fish Oil 50% DHA - 30% EPA***Dietary Supplement 100 Softgels***6 65176 05274 3***Manufactured for:HealthMax Products Co. Altadena, CA 91001***".
Recalled by Healthmaxx Global INC. on Jun 10, 2013
Reason for Recall
In response to a FDA inspection, the firm initiated this voluntary recall of various dietary supplements due to the following problems of mislabeling: 1) product named on the label is not actual product contained; 2)ingredients listed are not actual ingredients contained.
Product Description
Hyper II DHA/EPA, 100 Count Softgels. Product labeling reads in part:"Hyper II DHA/EPA Refined Deep Sea Fish Oil 50% DHA - 30% EPA***Dietary Supplement 100 Softgels***6 65176 05274 3***Manufactured for:HealthMax Products Co. Altadena, CA 91001***".
Distribution
CA, MD, and NY
What Should You Do?
- 1.Check your kitchen for this product immediately.
- 2.Do not consume the recalled product.
- 3.Return the product to where you bought it for a full refund, or throw it away.
- 4.If you have experienced any health issues, contact your healthcare provider.
Browse Related Recalls
Terms Explained
- Class II Recall — learn what this means in food safety
- FDA Food Recall — learn what this means in food safety
The this entity record above pulls directly from the FDA openFDA enforcement-report API. What follows is the per-entity context — how this entity sits in the broader U.S. FDA food, drug, and device recalls distribution and which underlying factors drive the headline numbers.
Every number on this page links back to the FDA openFDA enforcement-report API; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. consumer-product recalls. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.
Source: FDA Recalls, Market Withdrawals and Safety Alerts, 2026.